We are live on
!
Find out more
DP
Dearborn Partners Portfolio holdings
AUM
$1.85B
1-Year Est. Return
6.59%
This Fund
S&P 500
This Quarter
Est. Return
-1.19%
1 Year Est. Return
+6.59%
3 Year Est. Return
+44.33%
5 Year Est. Return
+68.05%
10 Year Est. Return
+241.41%
AUM
$2.39B
AUM Growth
-$77M
(-3.1%)
Cap. Flow
-$31.6M
Cap. Flow
% of AUM
-1.33%
Top 10 Holdings %
Top 10 Hldgs %
27.24%
Holding
278
New
12
Increased
90
Reduced
122
Closed
19
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Corteva
CTVA
|
+$31.8M |
| 2 |
Amphenol
APH
|
+$31.1M |
| 3 |
SPYM
State Street SPDR Portfolio S&P 500 ETF
SPYM
|
+$718K |
| 4 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$690K |
| 5 |
iShares iBonds Dec 2029 Term Corporate ETF
IBDU
|
+$522K |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Elevance Health
ELV
|
+$29.9M |
| 2 |
Gilead Sciences
GILD
|
+$20.6M |
| 3 |
Casey's General Stores
CASY
|
+$8.66M |
| 4 |
Cintas
CTAS
|
+$8.46M |
| 5 |
Reliance Steel & Aluminium
RS
|
+$4.76M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 25.72% |
| 2 | Industrials | 14.79% |
| 3 | Financials | 10.99% |
| 4 | Healthcare | 10.98% |
| 5 | Consumer Discretionary | 8.53% |
Similar funds
LOAME
OFS
SAMH
CPSAC
FCIM
ABTD
RP
JSAM
Dearborn Partners's Q4 2024 Portfolio in Review
As of Q4 2024, Dearborn Partners held 278 positions worth $2.39B, down 3.1% from $2.46B the previous quarter. Its ten largest holdings account for 27% of the portfolio.
Dearborn Partners's Q4 2024 filing shows 12 new, 90 increased, 122 reduced and 19 closed positions. Its largest new stake was iShares iBonds Dec 2029 Term Corporate ETF: 22,655 shares worth $517K. The largest sale was Elevance Health, an estimated $29.9M.
By sector, the portfolio is most concentrated in Technology at 26% of assets, up from 24% a quarter earlier, followed by Industrials and Financials.
- Dearborn Partners's largest Q4 2024 buy was iShares iBonds Dec 2029 Term Corporate ETF: 22,655 shares worth $517K.
- Dearborn Partners added most to Corteva in Q4 2024, an estimated $31.8M increase.
- Dearborn Partners's biggest Q4 2024 reduction was Gilead Sciences, cutting an estimated $20.6M.
- Dearborn Partners fully exited Elevance Health in Q4 2024, selling an estimated $29.9M.
- Dearborn Partners's ten largest holdings make up 27% of its $2.39B portfolio in Q4 2024.
- Dearborn Partners opened 12 new positions and closed 19 in Q4 2024.
- Dearborn Partners's portfolio value fell 3.1% quarter-over-quarter to $2.39B.
Based on Dearborn Partners's 13F filing for Q4 2024, filed 7 Feb 2025.